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Genotype-phenotype correlations provide another perspective in studies seeking to identify the factors that 
underlie the clinical variability that is a feature of several inherited diseases. This approach has been 
particularly revealing in investigations into the molecular causes and phenotypic heterogeneity associated 
with hypertrophic cardiomyopathy (HCM), a common inherited primary cardiac disorder.1 2 Although, as its 
name suggests, hypertrophy may be a noticeable feature of the disease, it is not invariant, nor does the 
degree of hypertrophy necessarily correlate with the risk of sudden cardiac death (SCD), which is the most 
feared consequence of HCM.3 4  
Molecular genetic investigations have shown that HCM is caused by more than 100 distinct mutations in at 
least seven different sarcomeric protein encoding genes.5 When the clinical features of HCM are correlated 
in a family context with the specific disease causing gene and its associated mutation, a recognisable pattern 
emerges. Essentially, mutations in the cardiac β myosin heavy chain gene (MYH7) are more often associated 
with echocardiographically detectable to marked hypertrophy and a variable risk of SCD, usually before the 
age of 35 years, which generally relates to the specific causative mutation.6 In striking contrast, mutations in 
the cardiac troponin T gene (TNNT2) are most frequently accompanied by subtle, or even undetectable, 
hypertrophy, yet confer a high risk of SCD in adolescence or young adulthood.3 4 Between these extremes 
lie the myosin binding protein C gene mutations, which are responsible for a considerably later age of onset 
of a steadily progressive form of hypertrophy, which may result in death from congestive heart failure later 
in life, more often than SCD.7 8 Further studies are needed before conclusive genotype-phenotype profiles 
can be defined for mutations in other HCM causing genes.9-11  
This stratification of HCM into distinguishable subclasses of disease has been used in prognostication and 
management and counselling of patients with this treatable, but currently incurable, disease. However, it is 
generally advised that this approach be undertaken with caution, as some phenotypic associations are based 
on limited patient numbers.12 Furthermore, there is concern that data generated for one ethnic group 
cannot necessarily be extrapolated to others.13 As a corollary, evidence suggests that diverse genetic and 
environmental susceptibility factors may modulate the expression of identified disease causing mutations in 
the sarcomeric protein encoding genes.14 15  
We previously described a novel MYH7mutation, resulting in the substitution of a threonine (T) residue for 
an alanine (A) residue at codon 797 (A797T), in two South African HCM patients. Initial impressions, based 
on the immediate family history of one of these unrelated subjects, were that this mutation was associated 
with a poor prognosis and frequent SCD, thus prompting further investigation.16 It was then found that both 
parents of the proband carried the MYH7 A797T mutation. Concomitantly, this mutation was identified in 
another seven apparently unrelated members of a panel of South African HCM patients. Subsequent 
haplotyping studies showed that the MYH7A797T mutation was a founder mutation extant in South African 
subpopulation groups, where it accounted for 25% of disease causes in a panel of HCM affected probands,17 
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making it even more important to investigate its associated phenotype. These studies were further 
warranted because the mutation carriers in the extended families traced from these probands shared a 
common ancestor and provided a large patient base in which to establish genotype-phenotype correlations.  
We show that the MYH7 A797T mutation is generally associated with a favourable prognosis, but that it is 
important to consider the influence of both genetic and environmental modifiers on the disease profile, 
when using genotype-phenotype correlations in patient management and counselling.  
The study subjects were probands belonging to a panel of South African HCM affected subjects and their 
relatives who could be traced. After obtaining informed consent from subjects or legal guardians, DNA was 
extracted from peripheral blood samples.18 TheMYH7 A797T mutation was detected by PCR based allele 
specific restriction enzyme analysis.16Mutation positive subjects were clinically evaluated as described 
previously.14 Briefly, echocardiographically determined end diastolic maximum left ventricular wall 
thickness (LVWT) measurements were obtained at the anterior interventricular septum (IVS) and posterior 
wall (PW). Echocardiographic diagnosis of HCM was made in the presence of an IVS ⩾13 mm, in the absence 
of confounding factors. Electrocardiographic diagnosis of HCM was based on the presence of left ventricular 
hypertrophy (LVH) according to the point system of Romhilt and Estes19 or a significant Q wave abnormality. 
A family history and clinical records were obtained to identify the range of symptoms noted in affected 
subjects and the number of disease related and sudden cardiac deaths (SCDs) reported among the families 
studied. The latter data were used to construct Kaplan-Meier survival curves.20 Based on the similarity of 
phenotype and survival, the survival data from affected subjects in all the families, except those belonging to 
pedigree 101, were pooled. Pedigree 101 was evaluated separately because both parents in kindred 101a 
(fig 1) carried theMYH7 A797T mutation and previous haplotype studies had shown them to be related.17 
Members of the pedigrees are identified by a pedigree number prefix, followed by the subject's 
identification numbers. The prefix SB identifies probands from whom relatives could not be traced. 
Pedigrees 101, 124, 131, and 138 were of white descent, while pedigrees 104 and 110 and subjects SB902, 
SB983, and SB995 were of ethnic admixture.17 In order to ascertain that two brothers carrying theMYH7 
A797T mutation were monozygotic (MZ) twins, their HinfI digested DNA samples were analysed by Southern 
blot hybridisation21 at hypervariable GTG genetic loci using the (GTG)5 fingerprinting probe.22 
A total of 66 family members of six pedigrees (pedigrees 101, 104, 110, 124, 131, and 138, fig 1) and three 
probands (SB902, SB983, and SB995) were genotyped for the MYH7 A797T mutation. Of these, 39 were 
mutation carriers (table 1), including both parents (1.II.2 and 1.II.3) of the proband (1.III.6) of kindred 101a, 
within pedigree 101 (fig 1). Additionally, three dead sibs of 1.III.6, namely 1.III.1, 1.III.3, and 1.III.5, were 
diagnosed with HCM at necropsy, implying that they were likely to have inherited at least one copy of the 
mutant allele from one of their carrier parents. Of these subjects, 1.III.1 was definitely a heterozygous 
mutation carrier, as one of her fraternal twin offspring (1.IV.2) had inherited the mutation, while the other 
(1.IV.1) had not. Similarly, dead subject 1.III.3 could not have been a homozygous mutation carrier, as he 
also had one non-carrier child (1.IV.3). No further assumptions could be made about the carrier status of 
dead subject 1.III.5, who died childless. No living homozygous mutation carriers were detected in this branch 
of pedigree 101. 
Thirty five of the 39 living mutation carriers were clinically examined, while 1.III.10, 4.II.3, 4.III.1, and 38.III.1 
declined clinical investigation. Subjects 38.II.1, 38.II.6, and 38.III.3 were assessed only by ECG and 4.I.1, 4.II.1, 
and 10.I.1 only by echocardiography.  
The mutation was associated with echocardiographically detectable hypertrophy of the IVS (LVWT ⩾13 mm) 
in 17 subjects (table 1), and although not to the same extent, the left PW and/or apex were also abnormal, 
with measurements of greater than 11 mm, in 11 of these subjects (table 1). Additionally, there were three 
mutation carriers whose LVWT measurements were ⩾11 but <13 mm. Moreover, SB902 and SB983 had 
undergone myectomy to reduce outflow tract obstruction, as well as mitral valve replacement. The mean 
LVWT, calculated for all mutation carriers ⩾16 years, was 17.1 mm (SD 8.6), while the median LVWT was 13 
mm.  
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Blood pressure measurements were below 160/95 mm Hg in 27 of the 29 mutation carriers for whom 
records were available (table 1), with the exceptions being two brothers, 31.III.6 and 31.III.8 (160/110 and 
150/100 mm Hg, respectively). Only three of these 29 mutation carriers were receiving blood pressure 
lowering medication at the time of the initial examination, namely, 31.III.6, who suffered kidney disease, and 
31.III.8 and 31.III.1.  
Only four subjects had electrocardiographically detectable LVH, evaluated by the point system of Romhilt 
and Estes19; these subjects had also shown an LVWT of ⩾13 mm (table 1). Additionally, 1.III.6 had had a 
pacemaker inserted. A further 12 subjects had other ECG abnormalities often noted in HCM, while their 
LVWT values varied between 10 and 40 mm. Of the remaining 15 subjects who did not display any ECG 
abnormalities, nine also did not meet the echocardiographic diagnostic criterion, while two had not been 
investigated by echocardiography and three were less than 16 years old (table 1).  
Disease penetrance among all mutation carriers was 61% (19/35 subjects), based on subjects older than 16 
years for whom an LVWT of ⩾13 mm was measured (32 subjects, table 1) or who were diagnosed with HCM 
at necropsy (three subjects).  
The symptomatic presentation of mutation carriers varied. Six of the 35 subjects for whom data were 
available complained of syncope or presyncope (1.II.2, 1.II.8, 1.III.6, 1.III.8, 31.III.4, SB902), three experienced 
dyspnoea (1.II.3, 1.III.8, 4.II.1), four suffered palpitations (1.II.8, 4.I.1, 31.III.1, 38.II.4), while six experienced 
both dyspnoea and palpitations (1.III.6, 1.IV.2, 10.II.1, SB902, SB983, SB995). Five subjects experienced 
angina (1.II.8, 1.III.6, 38.II.4, SB902, SB995), two suffered cardiac failure (1.II.2, 4.I.1), while three subjects 
developed both angina and cardiac failure (1.II.3, 4.II.1, SB983). However, further investigation of possible 
underlying ischaemic heart disease was not undertaken. Of the 35 clinically assessed mutation carriers, 19 
subjects, of whom four were under 16 years of age, had no reported symptoms.  
Proband 38.II.4 (fig 1) presented with chest pain and palpitations at the age of 38 years. He showed an LVWT 
of 12.7 mm at both the IVS and the left PW, and while his ECG tracings showed abnormal repolarisation and 
increased voltages (table 1), they did not meet the diagnostic criterion of LVH.19 However, taken together, 
the mild LVH, non-specific ECG changes, and symptoms, were likely to be HCM related. In contrast, his twin 
brother, 38.II.3, who was shown to be identical by band sharing on GTG fingerprinting, was symptom free, 
and exhibited an LVWT of 10 mm at the PW and 9 mm at the IVS. Although on ECG, 38.II.3 exhibited the 
same repolarisation abnormality and increased voltages as his twin, all other parameters, including similar 
blood pressure values, were normal. It was established from the proband's history that, while he had always 
been physically active, playing rugby football in high school and continuing to participate in competitive 
recreational cycling at the age of 38 years, his twin brother had generally avoided sport and exercise.  
In kindred 101a, three of the four offspring of parents 1.II.2 and 1.II.3 had suffered SCD (fig 1). These events 
occurred in 1.III.1, 1.III.3, and 1.III.5 at 26 years, 24 years, and 17 years of age, while they were walking, 
playing tennis, and during a period of heightened emotion, respectively. Three of their mother's pregnancies 
had terminated in spontaneous abortions and she suffered SCD while sedentary at the age of 58 years. In 
contrast, no sudden, or disease related, deaths were known to have occurred in the recent generations of 
any of the other pedigrees, including the remainder of pedigree 101. In pedigree 131, one pregnancy in 
31.II.3 had miscarried. The hypertensive father of the proband in pedigree 138 had died at 58 years of 
myocardial infarction, probably resulting from ischaemic heart disease. The Kaplan-Meier product limit 
curves for survival of the subjects with the MYH7 A797T mutation belonging to pedigree 101 and that of the 
rest of the families with this mutation, as well as that of South African families carrying the R92W mutation 
in TNNT2,3 are shown in fig 2. While survival in the other pedigrees was unimpeded, survival in pedigree 101 
was comparable to that of subjects bearing theTNNT2 R92W mutation with its previously described poor 
prognosis.3 
In this study, we have investigated the clinical phenotype associated with the HCM causative MYH7 A797T 
mutation in 35 mutation carriers, of whom 32 were members of six different apparently unrelated 
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pedigrees, and three were from families who could not be traced. The present study shows that, although 
the initial impressions were to the contrary,16 theMYH7 A797T mutation was generally associated with a 
good prognosis and normal life span, except in kindred 101a (figs 1 and 2).  
However, despite the usually favourable prognosis, the mutation was generally associated with 
echocardiographically detectable to overt hypertrophy, which was often marked (table 1). Two mutation 
carriers, SB902 and SB983, had undergone septal myectomy, to reduce outflow tract obstruction resulting 
from their cardiac hypertrophy, as well as mitral valve replacement. The mean (SD) LVWT in all the 
pedigrees, excluding pedigree 101, was 17.8 (SD 8.7 mm), with a range of 8-40 mm for subjects over 16 years 
old (table 1). In pedigree 101, the mean (SD) LVWT was similar to these values, namely 16.6 (SD 9.6 mm), 
with a range of 9-36 mm, which was shown by ANOVA to have no statistically significant difference from the 
rest of the families with this mutation.  
When considering survival, the only exception to the good prognosis associated with the MYH7 A797T 
mutation was in pedigree 101. Here, the high frequency of SCD was restricted to kindred 101a (figs 1 and 2), 
in which haplotyping studies had previously indicated that the parents of the proband, both of whom carried 
the MYH7 A797T mutation, shared a common ancestor.17 Three of the four offspring of the related 
mutation carrier parents in kindred 101a had died suddenly, before the age of 27 years. It is unlikely that 
these deaths resulted from a dosage effect of the mutant myosin protein, as at least two of them (1.III.1 and 
1.III.3) could not have been homozygous mutation carriers by virtue of their non-carrier offspring (fig 1). In 
contrast to the poor prognosis observed in kindred 101a, the mutation was not associated with any disease 
related deaths in the rest of pedigree 101, nor in the other families carrying the MYH7 A797T mutation (figs 
1 and 2).  
The data generated from genotype-phenotype assessments has led to speculation that HCM is not a simple 
monogenic disorder, as frequently the clinical manifestations and course of the disease differ even between 
subjects in the same family.14 15 For example, in the present study, there was marked variation in the 
degree of LVWT associated with the MYH7 A797T mutation within members of the same pedigree (table 1), 
indicating that the phenotypic expression of HCM causing mutations is modulated by additional factors. 
Whether these factors are genetic or environmental, and what the nature of the interplay between these 
factors and the major HCM causing mutations are, has been a topic of discussion in recent papers.15 23 24  
It can be speculated that the distinctive survival curve seen in pedigree 101 may result from the influence of 
genetic factors. In view of the shared ancestry of the parents in the nuclear family, it is possible that their 
offspring, who were deduced not to beMYH7 A797T homozygotes, may have been homozygous for 
susceptibility alleles at other loci that play a role in modulating expression of the main disease causative 
gene. Further support for the influence of deleterious homozygosity is that while the proband, 1.III.6, the 
remaining living child of parents sharing a common ancestor, showed overt septal hypertrophy (36 mm), and 
had undergone pacemaker implantation, his half brother, 1.III.8, showed moderate hypertrophy (13 mm). 
However, as the degree of relatedness of the parents in kindred 101a could not be established, this proposal 
remains speculative. It is unlikely that environmental factors alone could account for the malignant 
phenotype seen only in kindred 101a, as the clinical course associated with the founder mutation was benign 
in all other affected families, whose individual members were exposed to varied environments and life style.  
Evidence that environmental factors may also play a role in modulating the expression of main locus HCM 
causing mutations is provided by the divergent clinical presentation associated with theMYH7 A797T 
mutation in the identical twin brothers in pedigree 138. Whereas, the physically active twin, 38.II.4, was 
symptomatic and showed an LVWT of 12.7 mm, with the hypertrophy appearing concentric and 
concentrated around the apex, the LVWT in his asymptomatic brother, 38.II.3, measured only 10 mm. Earlier 
studies have also documented heterogeneity in the clinical expression of HCM in MZ twins,24 25 but this is 
the first report of MZ twins genotyped for a specific HCM causing mutation, in which clinical differences may 
directly relate to exercise. The influence of physical activity on the expression of the hypertrophic phenotype 
in HCM has been a cause of speculation, as exercise is known to produce the hypertrophy seen in “athletes' 
heart”.26 However, although these twins were considered genetically identical, it cannot be excluded that 
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epigenetic factors, or indeed environmental influences other than exercise, could also have played a role in 
the dissimilar development of hypertrophy.  
Currently, genotype-phenotype correlation studies provide the best available route to informed and 
accurate prognosis for improved patient management and risk stratification, with the caveat that these 
correlations should be based on substantial numbers of subjects drawn from the relevant ethnic group. In 
addition, it may also be prudent to consider the possible effects of shared ancestry and exercise on the 
clinical expression of a specific mutation, especially in subpopulation groups with known founder effects.  
Although these examples of divergent phenotypic expression in kindred 101a and the twins in pedigree 138 
are based on small numbers, they lend support to the notion that HCM is not a simple monogenic disorder 
and that both genetic and environmental factors are modifiers of the disease phenotype. A strategy followed 
in studies of disease phenotypes with multifactorial aetiology is to reduce the complexity of analysis by 
investigating genetically homogeneous subjects. The presence of the founder MYH7 A797T mutation 
suggests that the families harbouring it share a degree of common ancestry. We therefore propose that the 
presence of this HCM causing mutation with incomplete penetrance, in a substantial group of related 
people, provides an opportunity to investigate the role of additional factors involved in the development of 
the disease phenotype. Only when these factors are known will the puzzling variability in the clinical 
expression which is a feature of HCM mutations, and the true pathophysiology of this disease, be 
understood.  
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Table 
Table 1  
Echocardiographic and electrocardiographic features present in subjects carrying the A797T MYH7 mutation 
Subject No 
Sex/age 
(y) 
Echocardiograp
hic 
 
Electrocardiogra
phic 
BP 
IVS 
(mm) 
PW 
(mm) 
Area of 
hypertrophy 
AS
H 
SA
M 
Abn 
rep 
Inc 
volt
s 
Abn 
Q 
wave
s 
↑Atri
a 
LV
H 
1.II.2 
M/5
8 
12 10 
Ivs + 
apex 
 y n y n n n n 
130/8
0 
    
1.II.3 F/55 22 10 Ivs  y n y n y y n 
140/8
0 
    
1.II.6 F/53 9 8 NA  n n n n n n n 
110/8
0 
    
1.II.8 F/47 14 9 Ivs  y n n n n n n 
150/9
0 
    
1.III.6 
M/3
4 
36 13 Ivs + pw  y y PM PM 
P
M 
P
M 
PM 
140/8
0 
    
1.III.8 
M/2
9 
13 13 Ivs + pw  n n y n n n n 
120/7
0 
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Subject No 
Sex/age 
(y) 
Echocardiograp
hic 
 
Electrocardiogra
phic 
BP 
IVS 
(mm) 
PW 
(mm) 
Area of 
hypertrophy 
AS
H 
SA
M 
Abn 
rep 
Inc 
volt
s 
Abn 
Q 
wave
s 
↑Atri
a 
LV
H 
1.III.10 
M/3
0 
NI NI NI  NI 
N
I 
NI NI NI NI NI NI     
1.III.11 F/27 10 8 NA  n n n n n n n 
110/7
0 
    
1.IV.2  F/14 13 9 Ivs  y y y n y n n 
100/5
0 
    
1.IV.6  F/8 6 6 NA  n n n n n n n na     
4.I.1 F/70 8 8 NA  
N
A 
n na na na na na na     
4.II.1 
M/4
8 
24 12 Ivs + pw  y y na na na na na na     
4.II.3 
M/n
a 
NI NI NI  NI 
N
I 
NI NI NI NI NI NI     
4.II.6 F/33 9 9 NA  
N
A 
n n n n n n 
120/8
0 
    
4.III.1  F/10 NI NI NI  NI 
N
I 
NI NI NI NI NI NI     
10.I.1 F/32 24 10 Ivs  y n na na na na na 
100/7
0 
    
24.II.1 
M/5
6 
28 16 Ivs  y y y y n n n 
150/8
0 
    
24.III.2 
M/2
9 
12 12 Ivs + pw  
N
A 
n n n n n n 
130/8
0 
    
31.III.1 
M/5
2 
10 10 NA  n n y n n n n 
130/9
5 
    
31.III.4 
M/5
1 
18 11 
Ivs + 
apex 
 y n y n n n n 
125/8
5 
    
31.III.6 
M/5
7 
13 12 
Ivs + 
apex + 
pw 
 n n y n y n n 
160/1
10 
    
31.III.8 
M/5
4 
13 12 
Ivs + 
apex + 
pw 
 n n y n y y y 
150/1
00 
    
31.IV.1 
M/2
0 
10 10 NA  n n y n n n n 
130/8
0 
    
31.IV.2 
M/1
8 
9 10 NA  n n n n n n n 
120/6
0 
    
31.IV.3  
M/1
5 
7 7 NA  
N
A 
n n n n n n 
120/7
5 
    
31.IV.4 
M/2
3 
26 11 Ivs + pw  n y y n n n y 
130/6
0 
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Subject No 
Sex/age 
(y) 
Echocardiograp
hic 
 
Electrocardiogra
phic 
BP 
IVS 
(mm) 
PW 
(mm) 
Area of 
hypertrophy 
AS
H 
SA
M 
Abn 
rep 
Inc 
volt
s 
Abn 
Q 
wave
s 
↑Atri
a 
LV
H 
31.IV.5 
M/2
2 
23 8 Ivs  n y n n n n n 
120/7
0 
    
31.IV.6 
M/1
9 
40 na 
Ivs + 
apex 
 y y y n n n n 
110/7
0 
    
31.IV.8  F/15 10 10 NA  
N
A 
n n n n n n 
140/9
0 
    
31.IV.1
4 
M/2
7 
9 9 NA  n n n n n n n 
140/9
0 
    
38.II.1 
M/4
0 
na na na  na 
n
a 
n n n n n na     
38.II.3 
M/3
8 
9 10 NA  
N
A 
n y y n n n 
140/9
0 
    
38.II.4 
M/3
8 
12.
7 
12.
7 
Ivs + 
apex 
 n n y y n n n 
145/9
0 
    
38.II.6 
M/3
5 
na na na  na 
n
a 
n n n n n na     
38.III.1  F/12 NI NI NI  NI 
N
I 
NI NI NI NI NI NI     
38.III.3  F/13 na na na  na 
n
a 
n n n n n na     
SB902  F/27 
221
-150  
131
-150  
Ivs + pw  y y y n y y y 
110/6
0 
    
SB983  F/62 
161
-150  
161
-150  
Ivs + pw  y y y n y y y 
140/7
0 
    
SB995  
M/4
9 
25 15 Ivs + pw  y y n n n n n 
140/8
5 
    
 Abn Q waves = abnormal Q waves, Abn rep = abnormal repolarisation, Age = age at diagnosis, ASH = 
asymmetrical septal hypertrophy, ↑Atria = enlarged atria, BP = blood pressure (mm Hg), Inc volts = 
increased voltages, IVS (mm) = maximum end diastolic interventricular septal thickness in mm, Ivs = 
interventricular septum, LVH = left ventricular hypertrophy by Romhilt and Este's criteria, PW (mm) = 
maximum end diastolic posterior wall thickness in mm, pw = posterior left ventricular free wall, SAM 
= systolic anterior motion of the mitral valve, y = feature present, n = feature absent, NA = not 
applicable, na = records not available, NI = not investigated clinically,  
 1-150 = post myectomy values. Subjects under 16 years old are underlined.  
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Figures 
Figure 1  
Pedigrees in which the MYH7 A797T mutation segregated. The genotypic and phenotypic status of subjects is 
indicated in the key. Kindred 101a is shown on a shaded background.  
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Figure 2  
A comparison of Kaplan-Meier product limit curves for survival in subjects carrying the MYH7 A797T 
mutation and those carrying the previously reported TNNT2 R92W mutation.17 Survival data were combined 
and plotted for all MYH7 A797T families except for pedigree 101. Survival in pedigree 101 was similar to that 
of subjects with the TNNT2 R92W mutation (p=0.9), but was significantly worse than in the other families 
with the MYH7 A797T mutation (p=0.024).  
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